Internet Archive Scholar

Development and validation of an expanded carrier screen that optimizes sensitivity via full-exon sequencing and panel-wide copy-number-variant identification [article]

Gregory J. Hogan, Valentina S. Vysotskaia, Stefanie Seisenberger, Peter V. Grauman, Kyle A. Beauchamp, Kevin R. Haas, Sun Hae Hong, David Jennions, Diana Jeon, Shera Kash, Henry H. Lai, Laura M. Melroy (+11 others)
2017 bioRxiv   pre-print

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (1.1 MB)
https://web.archive.org/web/20190502150634/https://www.biorxiv.org/content/biorxiv/early/2017/08/20/178350.full.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

Purpose: By identifying pathogenic variants across hundreds of genes, expanded carrier screening (ECS) enables prospective parents to assess risk of transmitting an autosomal recessive or X-linked condition. Detection of at-risk couples depends on the number of conditions tested, the diseases' respective prevalences, and the screen's sensitivity for identifying disease-causing variants. Here we present an analytical validation of a 235-gene sequencing-based ECS with full coverage across coding
more » ... egions, targeted assessment of pathogenic noncoding variants, panel-wide copy-number-variant (CNV) calling, and customized assays for technically challenging genes. Methods: Next-generation sequencing, a customized bioinformatics pipeline, and expert manual call review were used to identify single-nucleotide variants, short insertions and deletions, and CNVs for all genes except FMR1 and those whose low disease incidence or high technical complexity precludes novel variant identification or interpretation. Variant calls were compared to reference and orthogonal data. Results: Validation of our ECS data demonstrated >99% analytical sensitivity and >99% specificity. A preliminary assessment of 15,177 patient samples reveals the substantial impact on fetal disease-risk detection attributable to novel CNV calling (13.9% of risk) and technically challenging conditions (15.5% of risk), such as congenital adrenal hyperplasia. Conclusion: Validated, high-fidelity identification of different variant types — especially in diseases with complicated molecular genetics — maximizes at-risk couple detection.
doi:10.1101/178350 fatcat:3nbprvtuynf3niz5vsshivtt7m
Citation

Gregory J. Hogan, Valentina S. Vysotskaia, Stefanie Seisenberger, Peter V. Grauman, Kyle A. Beauchamp, Kevin R. Haas, Sun Hae Hong, David Jennions, Diana Jeon, Shera Kash, Henry H. Lai, Laura M. Melroy, Mark R. Theilmann, Clement S. Chu, Saurav Guha, Kevin Iori, Jared R. Maguire, Kenny K. Wong, Eric A. Evans, Imran S. Haque, Rebecca Mar-Heyming, Hyunseok P. Kang, Dale Muzzey. "Development and validation of an expanded carrier screen that optimizes sensitivity via full-exon sequencing and panel-wide copy-number-variant identification." bioRxiv (2017)